WHO guidance on multidrug-resistant tuberculosis treatment: using and communicating the evidence

Dennis Falzon, Holger J. Schünemann, Matteo Zignol, Fuad Mirzayev, Tereza Kasaeva

Source: Eur Respir J, 55 (3) 1902325; 10.1183/13993003.02325-2019

Journal Issue: March

Disease area: Respiratory infections

Rating:

You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Dennis Falzon, Holger J. Schünemann, Matteo Zignol, Fuad Mirzayev, Tereza Kasaeva. WHO guidance on multidrug-resistant tuberculosis treatment: using and communicating the evidence. Eur Respir J, 55 (3) 1902325; 10.1183/13993003.02325-2019

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.

You must Login to comment this presentation.

Related content which might interest you:

Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? Source: Eur Respir J, 49 (5) 1700738; 10.1183/13993003.00738-2017 Year: 2017
Bedaquiline and multidrug-resistant tuberculosis: a systematic and critical analysis of the evidence Source: Eur Respir J 2016; 47: 394-402 Year: 2016
Multidrug-resistant tuberculosis in children: evidence from global surveillance Source: Eur Respir J 2013; 42: 701-707 Year: 2013
Ertapenem in the treatment of multidrug-resistant tuberculosis: first clinical experience Source: Eur Respir J 2016; 47: 333-336 Year: 2016
Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005
Management and treatment of multidrug-resistant tuberculosis Source: International Congress 2019 – Tuberculosis: latest advances and challenges in patient management Year: 2019
Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline Source: Eur Respir J , 49 (3) 1700146; DOI: 10.1183/13993003.00146-2017 Year: 2017
WHO 2019 guidelines on drug-resistant tuberculosis treatment: based on evidence or expert opinion? Source: Eur Respir J, 55 (3) 1901935; 10.1183/13993003.01935-2019 Year: 2020
Getting the best possible evidence from observational studies of treatment of multidrug-resistant tuberculosis patients Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights Year: 2013
Medico-surgical considerations when looking for treatment for multidrug-resistant TB Source: Eur Respir J 2002; 20: Suppl. 38, 361s Year: 2002
Surgical treatment of multidrug-resistant tuberculosis (MDR TB) Source: Eur Respir J 2003; 22: Suppl. 45, 523s Year: 2003
Evaluation of treatment outcomes for multidrug-resistant tuberculosis Source: Eur Respir J 2001; 18: Suppl. 33, 312s Year: 2001
Treatment of TB Source: Eur Respir Mon 2012; 58: 154-166 Year: 2012
Strategies against multidrug-resistant tuberculosis Source: Eur Respir J 2002; 20: 66S-77S Year: 2002
Comparison of two different cohorts of patients for multidrug-resistant tuberculosis treatment evaluation Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB) Year: 2006
Clinical and operational value of the extensively drug-resistant tuberculosis definition Source: Eur Respir J 2007; 30: 623-626 Year: 2007
Therapeutic drug management: is it the future of multidrug-resistant tuberculosis treatment? Source: Eur Respir J 2013; 42: 1449-1453 Year: 2013
A new era for treatment of drug-resistant tuberculosis Source: Eur Respir J, 52 (4) 1801350; 10.1183/13993003.01350-2018 Year: 2018
Paradoxical reactions in non-HIV tuberculosis presenting as endobronchial obstruction Source: Eur Respir Rev 2009; 18: 295-299 Year: 2009